737 / 1266
Phase III studies
High grade glioma
CCG (1989) (WHO III+IV)
58 EFS (5 years)
0.026
RT
18%
RT + (CCNU,VCR,Pred.)
46%
CCG (1995) (WHO III+IV)
PFS (5 years)
RT+ (CCNU,VCR,Pred.)
85
33%
n.s.
RT + „8 in 1“
87
36%
HIT – GBM A (2001) (Gr. IV)
med. survival
RT+ Troph/VP16
22
12 mon
(22% 4 y. EFS)
n.s.
RT / control (no chx.)
13
12 mon.
(4% 4 y. EFS)
Study Pat. survival
Signif.